Psychedelic Medicine Association

Psychedelic Medicine Association

Wellness and Fitness Services

A society of healthcare professionals dedicated to education regarding the therapeutic use of psychedelic medicines.

About us

The Psychedelic Medicine Association (PMA) is a professional association of healthcare practitioners that provides education and informational tools aimed at bridging the gap between the advances taking place in the psychedelic research world and medical practitioners. As most professional schools have not traditionally covered the therapeutic uses of psychedelics, and because new research is coming out regularly, the goal of the Psychedelic Medicine Association is to educate providers about the latest in both psychedelic research and the best practices in addressing these medicines with patients. Goals of the Psychedelic Medicine Association include: • Dissemination of the latest findings in psychedelic research • Increasing clinicians’ comfort with fielding patient questions about psychedelics • Providing guidelines for how to discuss psychedelics with patients • Encouraging practitioners to know the legal guidelines for how to discuss psychedelic medicines

Website
http://www.psychedelicmedicineassociation.org
Industry
Wellness and Fitness Services
Company size
2-10 employees
Headquarters
Worldwide
Type
Privately Held
Founded
2020

Locations

Employees at Psychedelic Medicine Association

Updates

  • We're very excited to announce this month's members-only webinar: Ketamine Therapy: Updates from the Field! Register: https://buff.ly/3LtQPoF As the date draws nearer for a final decision from the FDA on MDMA-assisted therapy, we thought it was a good time to keep hope alive by revisiting the currently-available psychedelic therapeutic: ketamine. Several new studies have been published since our last webinar on ketamine, and some new formulations have gotten attention as of late, so we wanted to check in with some of those on the front lines of ketamine therapy to find out what practices regarding ketamine therapy are working well and which may not be as effective. This month we are truly fortunate to have panelists working in ketamine clinics from three different areas of the country discussing a number of topics relevant to the therapeutic use of ketamine, including: • Advantages of Ketamine (compared to other psychedelics) • The future landscape of ketamine • What may happen to ketamine clinics as psychedelics get approved …and much more! Panelists joining us for this month's event are: Abid Nazeer, MD, FASAM | Founder & Chief Medical Officer, Hopemark Health David Feifel, MD, PhD | President & Founder, Kadima Neuropsychiatry Institute Greg Jones, CRNA, MS, BSN | Nurse Anesthetist, Co-Founder, & Clinic Director, Radiance Ketamine Clinic As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly! So please join us for this live panel discussion on Thursday, July 25th at 5 pm Pacific, 8 pm Eastern. Register: https://buff.ly/3LtQPoF

    • No alternative text description for this image
  • View organization page for Psychedelic Medicine Association, graphic

    11,694 followers

    The correct answer is vision! 37% answered correctly. Citation: https://lnkd.in/d3Ts8zE

    #Psychedelic knowledge check! The ability of #ketamine to re-open critical periods in neurodevelopment was first shown in its ability to restore ____ in mice. We'll reveal the answer next Tuesday!

    This content isn’t available here

    Access this content and more in the LinkedIn app

  • We're very excited to announce this month's members-only webinar: Ketamine Therapy: Updates from the Field! Register: https://buff.ly/3LtQPoF As the date draws nearer for a final decision from the FDA on MDMA-assisted therapy, we thought it was a good time to keep hope alive by revisiting the currently-available psychedelic therapeutic: ketamine. Several new studies have been published since our last webinar on ketamine, and some new formulations have gotten attention as of late, so we wanted to check in with some of those on the front lines of ketamine therapy to find out what practices regarding ketamine therapy are working well and which may not be as effective. This month we are truly fortunate to have panelists working in ketamine clinics from three different areas of the country discussing a number of topics relevant to the therapeutic use of ketamine, including: • Advantages of Ketamine (compared to other psychedelics) • The future landscape of ketamine • What may happen to ketamine clinics as psychedelics get approved …and much more! Panelists joining us for this month's event are: Abid Nazeer, MD, FASAM | Founder & Chief Medical Officer, Hopemark Health David Feifel, MD, PhD | President & Founder, Kadima Neuropsychiatry Institute Greg Jones, CRNA, MS, BSN | Co-Founder & Clinic Director, Radiance Ketamine Clinic As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly! So please join us for this live panel discussion on Thursday, July 25th at 5 pm Pacific, 8 pm Eastern. Register: https://buff.ly/3LtQPoF

    • No alternative text description for this image
  • The answer is Increased global integration! 43% answered correctly. Citation: https://lnkd.in/gSfDqYkF

    #Psychedelic knowledge check! Applying network #neuroscience to classical psychedelic neuroimaging data has revealed a complex array of acute effects on large-scale brain networks, such as the default mode network (DMN), with some contradictory results. Which of the following network effects is most robust? We'll reveal the answer next Tuesday!

    This content isn’t available here

    Access this content and more in the LinkedIn app

  • #Psychedelic knowledge check! Applying network #neuroscience to classical psychedelic neuroimaging data has revealed a complex array of acute effects on large-scale brain networks, such as the default mode network (DMN), with some contradictory results. Which of the following network effects is most robust? We'll reveal the answer next Tuesday!

    This content isn’t available here

    Access this content and more in the LinkedIn app

  • The answer is the TrkB-mTOR pathway! 66% answered correctly. Citation: https://lnkd.in/gNZty-Dq

    #Psychedelic knowledge check! Which cellular signaling pathway is implicated in the mediation of psychedelic-induced plasticity? We'll reveal the answer next Tuesday!

    This content isn’t available here

    Access this content and more in the LinkedIn app

Similar pages

Browse jobs